{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:22:53Z","timestamp":1785187373784,"version":"3.55.0"},"reference-count":40,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2567190","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:47:00Z","timestamp":1759477620000},"page":"1779-1797","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of enfortumab vedotin plus pembrolizumab as\u00a0a\u00a0first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States"],"prefix":"10.1080","volume":"28","author":[{"given":"Yang","family":"Meng","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research, Lumanity","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Aout","sequence":"additional","affiliation":[{"name":"BARDS HTA Statistics, MSD Innovation and Development GmbH","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Babcock","sequence":"additional","affiliation":[{"name":"Value & Implementation Outcomes Research, Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[{"name":"Value & Implementation Outcomes Research, Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Lai","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brand-Wiita","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Lumanity","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Notinger","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Lumanity","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhi","family":"Bavle","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"American Cancer Society. Key statistics for bladder cancer. 2025 [2025 Apr 3]. Available from: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html"},{"key":"e_1_3_4_3_1","unstructured":"National Cancer Institute. SEER*Explorer: an interactive website for SEER cancer statistics 2024. [updated 2024 Nov 5; 2025 Apr 3]; 2024 Apr 17. Available from https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.483"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.664"},{"key":"e_1_3_4_9_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) bladder cancer 2025 [updated 2025 Mar 25; 2025 Jul 6]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.03.010"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241295544"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464092"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.10.003"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_4_16_1","unstructured":"Institute for Clinical and Economic Review. Reference case for economic evaluations: principles and rationale. ICER; 2020 [updated 2023 Sep 23 2024 Sep 30]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/Reference-Case-4.3.25.pdf"},{"key":"e_1_3_4_17_1","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual Process and methods. PMG36; 2022 [updated 2022 Jan 31 2022 Mar 3]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"key":"e_1_3_4_18_1","unstructured":"Merck Sharp & Dohme LLC. BARDS health technology assessment statistical report: compound: MK-3475 protocol(s): A39 indication: 1st line urothelial cancer database cutoff: 8th August 2024 (final analysis). 2025. Data on file."},{"issue":"19","key":"e_1_3_4_19_1","first-page":"1","article-title":"United States life tables, 2019","volume":"70","author":"Arias E","year":"2022","unstructured":"Arias E, Xu J. United States life tables, 2019. Natl Vital Stat Rep. 2022;70(19):1\u201359.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.731"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds583"},{"key":"e_1_3_4_22_1","unstructured":"Merck Sharp & Dohme LLC. Keytruda (MK-3475) network meta analysis (NMA): enfortumab vedotin + pembrolizumab (KN-A39) vs. nivolumab (CheckMate-901) protocol A39: previously untreated locally advanced or metastatic urothelial cancer database cutoff: 08-Aug-2024 (final analysis). 2025. Data on file."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16547"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290495"},{"key":"e_1_3_4_25_1","unstructured":"U.S. Bureau of Labor Statistics. Consumer Price Index for all urban consumers (CPI-U) \u2013 medical care in U.S. city average all urban consumers not seasonally adjusted. 2024 [updated 2025 May 14; 2025 May 14]. Available from: https:\/\/www.bls.gov\/data\/#prices"},{"key":"e_1_3_4_26_1","unstructured":"Micromedex. Redbook 2024. [2025 May 14]. Available from: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/redbook.ModifyRedBookSearch"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.013"},{"key":"e_1_3_4_28_1","unstructured":"Centers for Medicare and Medicaid Services. Physician fee schedule lookup tool 2024 [updated 2024 Oct 17; 2024 Nov 05]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=0&H1=96417&M=5"},{"key":"e_1_3_4_29_1","unstructured":"AHRQ. Healthcare Cost and Utilization Project (HCUPnet). 2024 [2024 Oct 29]. Available from: https:\/\/datatools.ahrq.gov\/hcupnet\/"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.714"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1792"},{"key":"e_1_3_4_32_1","unstructured":"Institute for Clinical and Economic Review. ICER 2019 perspectives on cost-effectiveness threshold ranges. ICER; 2019. Available from: https:\/\/icer.org\/wp-content\/uploads\/2023\/08\/ICER_2019_Perspectives-on-Cost-Effectiveness-Threshold-Ranges.pdf"},{"key":"e_1_3_4_33_1","unstructured":"Macrotrends. U.S. GDP per capita 1960-2025. 2025 [2025 May 14]. Available from: https:\/\/www.macrotrends.net\/global-metrics\/countries\/USA\/united-states\/gdp-per-capita"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.10.001"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7070"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.07.014"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.06.001"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02273-4"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer.15.50"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.536"},{"key":"e_1_3_4_41_1","volume-title":"NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching","author":"Latimer NR","year":"2014","unstructured":"Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. London: National Institute for Health and Care Excellence (NICE); 2014."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2567190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:47:20Z","timestamp":1766400440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2567190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2567190"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2567190","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}